Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
This atypical deal structure will see Gilead collaborate with Galapagos to develop gamgertamig for the treatment of B-cell mediated autoimmune diseases.
This atypical deal structure will see Gilead collaborate with Galapagos to develop gamgertamig for the treatment of B-cell mediated autoimmune diseases.
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?